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Late-infantile neuronal ceroid lipofuscinosis (CLN2 disease) is a hereditary neurological disorder char-
acterized by progressive retinal degeneration and vision loss, cognitive and motor decline, seizures, and
pronounced brain atrophy. This fatal pediatric disease is caused by mutations in the CLN2 gene which
encodes the lysosomal enzyme tripeptidyl peptidase-1 (TPP1). Utilizing a TPP1/ Dachshund model of
CLN2 disease, studies were conducted to assess the effects of TPP1 enzyme replacement administered
directly to the CNS on disease progression. Recombinant human TPP1 (rhTPP1) or artiﬁcial cerebrospinal
ﬂuid vehicle was administered to CLN2-affected dogs via infusion into the CSF. Untreated and vehicle
treated affected dogs exhibited progressive declines in pupillary light reﬂexes (PLRs) and electroreti-
nographic (ERG) responses to light stimuli. Studies were undertaken to determine whether CSF
administration of rhTPP1 alters progression of the PLR and ERG deﬁcits in the canine model. rhTPP1
administration did not inhibit the decline in ERG responses, as rhTPP1 treated, vehicle treated, and
untreated dogs all exhibited similar progressive and profound declines in ERG amplitudes. However, in
some of the dogs treated with rhTPP1 there were substantial delays in the appearance and progression of
PLR deﬁcits compared with untreated or vehicle treated affected dogs. These ﬁndings indicate that CSF
administration of TPP1 can attenuate functional impairment of neural pathways involved in mediating
the PLR but does not prevent loss of retinal responses detectable with ERG.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Childhood-onset neuronal ceroid lipofuscinoses (NCLs) are
autosomal recessively inherited lysosomal storage disorders char-
acterized by progressive vision loss culminating in blindness,
cognitive andmotor decline, and seizures (Haltia and Goebel, 2012;
Mole et al., 2011). The NCLs are almost always fatal. Clinical signs of
NCL result from widespread, progressive neurodegeneration
accompanied by accumulation of autoﬂuorescent lysosomal stor-
age bodies in CNS and other tissues, including the retina (Haltia,
2006). There are currently no effective treatments for any of the
multiple forms of NCL, although enzyme replacement therapy forool of Medicine, Mason Eye
USA. Tel.: þ1 573 882 8480;
Katz).
Ltd. This is an open access article uthe CLN2 disease form is being tested clinically (ClinicalTrials.gov
Identiﬁer: NCT01907087).
Development of effective therapies is facilitated by the avail-
ability of suitable animal models. Naturally occurring NCLs have
been identiﬁed in several larger animal species, including dogs
(Awano et al., 2006a, 2006b; Bond et al., 2013; Farias et al., 2011;
Katz et al., 2005, 2011; O'Brien and Katz, 2008; Palmer et al.,
2011; Sanders et al., 2010). Among the canine NCLs, long-haired
Dachshunds have a null mutation in TPP1 which encodes the
lysosomal enzyme tripeptidyl-peptidase-1 (TPP1) (Awano et al.,
2006b). Neurological signs in children with mutations in CLN2
(the human ortholog of TPP1) typically appear between 2 and 4
years of age. Affected children suffer from progressive vision loss
and profound progressive neurological decline. The neurological
deterioration and accompanying brain atrophy associated with
CLN2 disease ultimately leads to death, usually by the middlender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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hunds homozygous for a TPP1 null mutation develop neurological
signs and vision loss that recapitulates the disease progression
observed in childrenwith CLN2 disease and reach end stage disease
between 10 and 11 months of age (Awano et al., 2006b; Katz et al.,
2008; Sanders et al., 2011; Vuillemenot et al., 2011).
TPP1 is a soluble lysosomal enzyme that plays an important role
in protein catabolism. Like other soluble lysosomal enzymes, TPP1
is not only localized within lysosomes, but is also discharged from
cells and taken back up via cell surface receptors that recognize the
mannose 6-phosphate moieties common to many lysosomal en-
zymes. TPP1 is synthesized as a glycosylated proenzyme that is
activated by proteolytic cleavage of an N-terminal fragment after
incorporation into lysosomes (Guhaniyogi et al., 2009). TPP1 pro-
enzyme supplied exogenously to cells is taken up via cell surface
mannose 6-phosphate receptors and is transported via the endo-
somal system to lysosomes where it is activated (Kytt€al€a et al.,
2006; Sohar et al., 1999). Therefore, CLN2 disease is amenable to
TPP1 enzyme replacement therapy (ERT). Because large molecules
such as TPP1 cannot cross the bloodebrain barrier, delivery of the
enzyme to the brain has been achieved through administration of
TPP1 pro-enzyme by infusion into the cerebrospinal ﬂuid (CSF) in
mouse and dog (Chang et al., 2008; Vuillemenot et al., 2011). In the
Dachshund CLN2 disease model, we have previously shown that
this route of TPP1 administration results inwidespread distribution
of the active enzyme in many structures of the brain and in
reduction in the accumulation of neuronal lysosomal storage ma-
terial that is characteristic of this disease (Vuillemenot et al., 2011).
In addition, biweekly enzyme infusions delayed the onset and
progression of neurologic signs and brain atrophy, improved
cognitive function, and substantially extended lifespan in the
Dachshund model (Katz et al., 2014).
If TPP1 infused into the CSF can reach the tissues involved in
retinal-mediated light responses, this treatment may preserve vi-
sual function as well. Quantitative evaluation of the pupillary light
reﬂex (PLR) in conjunction with electroretinogram (ERG) assess-
ment is a sensitive tool to evaluate the integrity of the entire
complex network of neuronal circuitry involved in modulating
pupil size, including the retina fromwhich the signals originate that
generate the PLR (Fotiou et al., 2000; Park et al., 2011;Whiting et al.,
2013a). Utilizing the PLR in conjunction with the ERG can be
particularly useful in characterizing diseases such as CLN2 inwhich
pathological changes occur in both the retina and other areas of the
CNS involved in mediating the PLR and in assessing the pharma-
cological activity of therapeutic interventions.
Dogs affected with CLN2 disease present with marked decline in
retinal function as demonstrated by reduced ERG b-wave ampli-
tudes by 5 months of age and signiﬁcant thinning of the inner
retina by disease end-stage (Katz et al., 2008;Whiting et al., 2013a).
In addition, affected dogs exhibit signiﬁcant deﬁcits in PLR latency,
constriction velocity, constriction amplitude, and both initial andTable 1
Experimental treatment groups.
Genotype Treatment n
Normal TPP1þ/þ Untreated 7
Vehicle Treated 3
Enzyme Treated: 16 mg rhTPP1 3
Enzyme Treated: 4 mg rhTPP1 3
Affected TPP1/ Untreated 5
Vehicle Treated 3
Enzyme Treated: 4 mg rhTPP1 3
Enzyme Treated: 16 mg rhTPP1 3
Enzyme Treated: 48 mg rhTPP1 2secondary redilation velocity, particularly with dim light stimuli
(Whiting et al., 2013a). We hypothesized that these PLR deﬁcits
result not only from retinal degeneration but also from disease-
related degenerative changes in the CNS nuclei involved in medi-
ating the PLR and that providing rhTPP1 to the CNS would inhibit
development of these deﬁcits. Studies were therefore undertaken
to determine whether chronic administration of pro-rhTPP1 into
the CSF could ameliorate PLR deﬁcits associated with CLN2 disease.
2. Materials and methods
2.1. Animals
Studies employed long-haired miniature Dachshunds bred and
housed in a research facility at the University ofMissouri. A research
colony was established by breeding from an original pair of
Dachshunds that were heterozygous for a one nucleotide deletion
in TPP1 (Awano et al., 2006b). Puppies were genotyped within
several weeks of birth at the TPP1 locus using an allelic discrimi-
nation assay that distinguishes the normal and mutant alleles
(Awano et al., 2006b). Most breeding consisted of carrier to carrier
crosses, but periodically carrier males were bred to unrelated
normal females to maintain genetic heterogeneity in the colony.
Dogs utilized in this study were either homozygous normal
(TPP1þ/þ) (n¼ 16) or homozygous for themutant allele (TPP1/)
(n ¼ 16). Heterozygous carriers of the TPP1 mutation (TPP1 /þ)
were not evaluated for responses to light stimuli. Dogs were
entrained to a 12:12 daily light cycle and were socialized daily in
addition to receiving routine husbandry care. All studies were
performed in compliance with the EU Directive 2010/63/EU for
animal experiments and the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and were approved by the
University of Missouri Animal Care and Use Committee.
2.2. Ophthalmic examinations
Prior to inclusion in the study, all dogs received a complete
ophthalmic examination at 10e12 weeks of age, before the onset of
any signs of retinal or neurological impairment due to CLN2 disease
(Katz et al., 2008; Whiting et al., 2013a). Any dogs with evidence of
vision compromise or ophthalmic conditions deemed threatening
to vision were excluded from the study (n ¼ 1). Examinations were
repeated monthly for CLN2-affected dogs and every other month
for genetically normal dogs. Examinations included assessment of
visual tracking behavior, slit lamp biomicroscopy, and indirect
ophthalmoscopy. Slit lamp biomicroscopy was performed prior to
dilation (SL14; Kowa Co. Ltd., Tokyo, Japan). Pupils were dilated
with a short-acting mydriatic (tropicamide 1%; Alcon, Fort Worth,
TX) prior to indirect ophthalmoscopy which was performed using a
wireless indirect headset (12,500, Welch Allyn Inc., Skaneateles
Falls, NY, USA) and a handheld lens (30 diopter clear lens, Volk
Optical Inc., Mentor, OH). Fundus photographs were taken
following examination (NM-100; Nidek Co. Ltd., Freemont, CA) and
archived electronically. Photos were reviewed to evaluate for
changes in retinal appearance.
2.3. Delivery of replacement enzyme
Recombinant human pro-TPP1 (rhTPP1) was synthesized and
puriﬁed as described previously and formulated in artiﬁcial CSF (Lin
and Lobel, 2001). Artiﬁcial CSF (vehicle) was administered alone to
vehicle control dogs.
At approximately 2 months of age, two catheters were
implanted in each dog. One catheter terminated in a lateral
ventricle of the brain (ICV catheter) and the other in subarachnoid
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cutaneous titanium access ports anchored in the fascia of the
respective muscle and subcutaneous tissues of the cervical and
lumbar regions. Detailed descriptions of the catheter and port im-
plantation procedures are provided in the Supplemental Materials
section.
Starting 2 weeks after the catheter implantation surgeries, test
or control articles were administered via infusion through the ICV
catheters once every other week (Table 1). Each infusion was per-
formed over a 2e4 h period, depending on dose. The 4 mg doses
were administered over 2 h infusion periods and the higher doses
were administered over 4 h infusion periods. The dogs were
sedated with buprenorphine (0.015 mg/kg) and dexmedetomidine
(30e40 mcg/kg). The treatment groups are listed in Table 1.
After 4 months of age, prior to each infusion, the locationwithin
the lateral ventricle and patency of the ICV catheterwas assessed by
computed tomography of the brain after infusion of 0.1 ml of the
nonionic contrast agent Iohexol (GE Healthcare). Over time, the ICV
catheter in most animals either became occluded or the tip
migrated into the brain parenchyma due to growth of the cranial
cavity. When this occurred, the infusion site was switched from the
ICV to the ITL catheter. Eventually, the ITL catheters usually became
occluded as well. When this occurred, the treatment administration
was continued by bolus injection into the subarachnoid space at the
cerebellomedullary cistern over 2 min.
2.4. PLR recordings
The PLR was recorded in each dog at 8, 10 and 12 months of age.
PLR recordings were also obtained at 15 months of age in two
treated, affected dogs that received the 16 and 48 mg doses and
three normal dogs that were either untreated (n ¼ 2) or received
the 16 mg dose (n ¼ 1). Due to the need for euthanasia prior to the
recording time point, the 10 month recording was not obtained in
two of the vehicle treated dogs. For the same reason, the 12 month
recording was not obtained in two of the treated, affected dogs
(4 mg rhTPP1 (n¼ 1); 48mg rhTPP1 (n¼ 1)) or any of the untreated
or vehicle treated affected dogs. All recordings were done during
the light period of the daily 12:12 lightedark cycle. The detailed
methods for obtaining the PLRs have been described previously
(Whiting et al., 2013b). Dogs were kept in dim light (0.9 lux) for at
least 1 h, including preparation time, and in complete darkness for
10min prior to recording. After 30min of dim light adaptation, dogs
were pre-medicated with dexmedetomidine (20e25 mg/kg IM)
prior to induction of anesthesia with propofol [IV to effect,
1.49 ± 0.59 mg/kg (mean ± SD); PropoFlo 28, Abbott Laboratories,
Abbott Park, IL]. Dogs were intubated with a cuffed endotracheal
tube and anesthesia maintained with isoﬂurane (1.5% vaporizer
setting; Terrell, Piramal Healthcare, Boise, ID) in oxygen. A lid
speculum was inserted to ensure that the nictitating membrane
and eyelids did not interfere with light exposure or visualization of
the pupil. In addition, a small stay suture was placed in the bulbar
conjunctiva on the central axis approximately 5 mm superior to the
limbus to facilitate globe manipulation to maintain centration of
the pupil on the optical axis of the recording apparatus. The eyewas
regularly lubricated with saline eye wash solution throughout the
procedure.
Unilateral recordings were performed with a custom apparatus
(Whiting et al., 2013a; Fan et al., 2009) capable of timed delivery of
a visible light stimulus from a mounted high-power broad spec-
trum LED (MCWHL2; Thorlabs Inc., Newton, NJ) and concurrent
recording of pupil images at 30 frames per second using an
infrared-sensitive camera (PC164CEX-2; Supercircuits Inc., Austin,
TX) and continuous infrared illumination (880 nm LED) for visu-
alization of the eye. The direct PLR of the right eye was evaluatedusing a standardized protocol of 100 ms ﬂashes of broad spectrum
white light at each of 10 intensities between 8 and 15 log photons/
cm2/s.
Pupil images were analyzed using the batch processing feature
in Photoshop (Adobe Systems Inc; San Jose, CA). A list of image
frame number and corresponding pupil area was exported to a
spreadsheet and used to calculate desired parameters. Area mea-
surements were converted from pixels to mm2 based on the known
size of the lid speculum present in each pupil image (Whiting et al.,
2013b).
2.5. PLR parameters
For the studies described here, baseline pupil area was the
average pupil area, in a dark-adapted dog, over a 1 s period before
the light stimulus. Baseline pupil diameter was calculated from area
measurements of the circular pupil. PLR constriction amplitudewas
deﬁned as the difference between baseline pupil area and mini-
mum pupil area attained following the light stimulus. These values
were then converted to a percentage of baseline pupil area. Latency
was deﬁned as the time between stimulus onset and the beginning
of pupil constriction. Average constriction velocity was calculated
as the constriction amplitude divided by the constriction time,
where constriction time is calculated between the beginning of
pupil constriction and the minimum pupil size.
Redilation of the pupil is biphasic with a fast initial redilation
and slower secondary redilation. Average redilation velocity was
calculated for the initial redilation phase as half the constriction
amplitude divided by the time required for the pupil to redilate
from its minimum size to half the baseline pupil size. For the
brightest ﬂash (15 log photons/cm2/s), the average rate of second-
ary redilation was calculated for the period from 15 to 85 s after
light offset.
2.6. Electroretinography
Beginning at 2 months of age, bilateral ERG evaluations were
performed monthly as previously described (Katz et al., 2008). For
ages at which dogs underwent PLR assessment, ERG evaluationwas
performed within one week after the PLR recording session. Dogs
were prepared for ERG recording in ordinary room light. Prior to
recording, both pupils were dilated with 1% tropicamide, and dogs
were deeply sedated with intramuscular administration of dex-
medetomidine (30e40 mg/kg). Ketamine (up to 5 mg/kg) was used
in combination with the dexmedetomidine for dogs 6 months of
age and younger to achieve adequate sedation. It was omitted in
older dogs to reduce the risk of seizure associated with CLN2, and it
was no longer necessary for adequate sedation with this age group.
ERGs were bilaterally elicited and simultaneously recorded with
a portable unit (HMsERGmodel 2000; RetVet Corp., Columbia, MO).
The right and left mini-ganzfeld domes were positioned approxi-
mately 2 cm from the corresponding eye. Each ERG session con-
sisted of scotopic and photopic recordings in accordance with the
Dog Diagnostic Protocol, recommended by the European College of
Veterinary Ophthalmology, primarily for evaluation of rod and cone
function (Narfstr€om et al., 2002). Throughout a 20 min period of
dark adaptation, scotopic low-intensity rod responses were elicited
at a stimulus intensity of 10.2 log photons/cm2/s (0.01 cd/m2) with
4 min of dark adaptation between recordings. Thereafter, scotopic
responses were elicited using ﬂashes of 12.65 and 13.2 log photons/
cm2/s (3 cd/m2 and 10 cd/m2) to evaluate mixed rod and cone
function. The eyes were then exposed to diffuse white light at a
luminance of 13.65 log photons/cm2/s (30 cd/m2) for 10 min,
immediately after which responses to single 12.65 log photons/
cm2/s (3 cd/m2) ﬂash stimuli were recorded. This was immediately
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stimuli at the same light intensity. ERG waveforms in all recordings
were evaluated, and the amplitudes and implicit times for the a-
and b-waves were measured as previously described (Marmor
et al., 2004).2.7. Optic nerve axon number determinations
Affected Dachshunds were euthanized at end stage disease and
related homozygous normal Dachshunds were euthanized at
similar ages (11e15months). Immediately after euthanasia the eyes
were enucleated and an approximately 10 mm long segment of the
optic nerve was dissected from immediately behind the globe and
ﬁxed in 2% glutaraldehyde, 1.12% paraformaldehyde, 130 mM so-
dium cacodylate, 1 mM CaCl2 at pH 7.4. Approximately 3 mm long
segments of the optic nerves were post-ﬁxed in osmium tetroxide
and embedded in epoxy resin. Cross sections of these samples were
cut at a thickness of 0.4 mm, mounted on slides and stained with
toluidine blue. Composite high resolution images of the entire cross
section of each optic nerve were obtained as described previously
(Morgan et al., 2014) (Fig. 1). Axon numbers in two size classes
(greater than and less than 7.8 mm2 in cross-sectional area) were
determined using Adobe Photoshop Touch and Metamorph (Mo-
lecular Devices, Sunnyvale, CA).2.8. Statistical analysis
All statistical tests were performed using SigmaPlot (Systat Soft-
ware Inc., San Jose, CA). Datawere subjected to the ShapiroeWilk test
to conﬁrm normal distribution. Results from all genetically normal
dogs (TPP1þ/þ), including those that were left untreated, those that
received infusions of vehicle, and those that received infusions of
rhTPP1 were combined to serve as the normal control group. Results
from CLN2-affected dogs that received infusions of vehicle were
combined with those from untreated, affected dogs to serve as the
disease control group. Pairwise comparisons did not detect any sig-
niﬁcant differences in any of the parameters that were measured
between groups thatwere combined for the ﬁnal statistical analyses.Fig. 1. (A) Composite image of an optic nerve cross-section used for axon number and size a
that individual axons could be clearly distinguished for counting and size determinations.For the ERGandPLRdata, repeatedmeasures 2-wayANOVAwasused
to compare results from affected dogs treatedwith rhTPP1 to each of
these control groups to determine if enzyme replacement therapy
was able to normalize any PLR or ERG deﬁcits related to CLN2 disease
progression. Follow-up pairwise comparisons were performed with
the Holm-Sidak correction (a ¼ 0.05) to control family-wise error
rate. For the optic nerve axon count data, comparisons between
untreated, affected and normal dogswere performed using Student's
t-test. Because no signiﬁcant effect of the disease alone onoptic nerve
axon number was detected (see results), no attempt was made to
assess whether there was an effect of rhTPP1 treatment on this
parameter.3. Results
3.1. Ophthalmic examinations
Initial examination in all dogs revealed normal adnexal and
ocular structures. Some CLN2-affected (TPP1 /) dogs in each of
the treatment groups developed progressive, multifocal retinal
detachment lesions between the ages of 5 and 11 months (n ¼ 11).
These disease-related lesions have been described previously
(Pearce et al., 2012). The lesions did not signiﬁcantly alter the PLR or
ERG except in advanced cases affecting over 50% of the retina
(Whiting et al., unpublished data), which occurred in one of the
untreated dogs at 10 months of age. In order to avoid confounding
factors, the data collected when severe lesions were present were
excluded from the study. Other CLN2-affected dogs retained
phenotypically normal fundus exams throughout the study period
(n ¼ 6). Homozygous normal (TPP1 þ/þ) dogs had consistently
normal ophthalmic examinations throughout the study period.3.2. PLR
CLN2-affected dogs that were left untreated and vehicle controls
exhibited signiﬁcantly reduced PLR constriction amplitudes by 8
months of age with stimuli between 9 and 12 log photons/cm2/s
(Figs. 2 and 3). These deﬁcits were even more pronounced by 10nalyses. (B) Enlarged image of one area of the composite at a magniﬁcation illustrating
Fig. 3. PLR constriction amplitudes from 8 month old dogs (mean ± SEM). Treated data
are broken into 2 groups of dogs with group R (n ¼ 3) showing a treatment response
and having normal constriction amplitudes that are signiﬁcantly different from those
of vehicle treated and untreated, CLN2-affected dogs (*, p < 0.001; y, p < 0.01). Treated
dogs from group NR (n ¼ 5) show no response to treatment and mimic deﬁcits seen in
the vehicle treated and untreated dogs (n ¼ 8).
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variability in the treatment effect that did not depend on treatment
dose level (Table 2). Of the eight dogs treated with rhTPP1, three
dogs (4 mg rhTPP1 (n ¼ 2); 16 mg rhTPP1 (n ¼ 1)) retained normal
PLR constriction amplitude through 10 months of age indicating a
response to treatment (Group R) (Table 2; Fig. 2). In the remaining
treated dogs, however, treatment did not preserve the PLR (Group
NR) and the PLR changes mimicked the deﬁcits in constriction
amplitude observed in untreated, affected dogs at both 8 and 10
months of age (Table 2; Figs. 3 and 4). These trends were also
observed for other PLR parameters with Group R treated dogs
exhibiting normal latency, constriction velocity, and initial redila-
tion velocity, particularly with low stimulus intensities (Fig. 5).
(Whiting et al., 2013a, 2013b). Group NR treated dogs, however,
exhibited deﬁcits in each of these parameters characteristic of
untreated CLN2 dogs (Whiting et al., 2013a).
Sample size decreased with age because of the need for eutha-
nasia prior to the 10,12, and 15 month recording time points due to
the symptoms associated with end-stage disease. A single un-
treated dog was removed from the study prior to the 10 month
recording due to the development of severe retinal lesions.
By 12 months of age, enzyme treated, CLN2-affected dogs from
Group R that initially exhibited normal PLR constriction ampli-
tudes, began to show PLR deﬁcits indicating a waning effect of the
treatment (Fig. 6). However, constriction amplitudes in Group R
were still signiﬁcantly increased over those of dogs that did not
respond to treatment (Group NR) for stimuli of 9 and 10 log pho-
tons/cm2/s (p < 0.05).
Deﬁcits in PLR constriction amplitude at 15 months of age
(Fig. 7) were very similar for both dogs treated with rhTPP1 that
survived to this age, which included one dog that initially respon-
ded to treatment and one dog that did not respond to treatment.
However, the change between 12months and 15months of agewas
much more pronounced in the dog that responded to treatment
and initially retained normal PLR parameters (Fig. 7). PLR threshold
at 15 months of age was increased by over 3 log units from the
average threshold for this group (R) at 12 months of age. For the 15
month old dog that initially responded to treatment, these PLR
changes coincided with end-stage disease. However, the 15 month
old dog from the non-responding group (NR) had only begun to
show neurologic signs of disease. Both 15 month old dogs hadFig. 2. Representative PLR traces from a normal dog, a CLN2-affected dog that
responded to treatment with rhTPP1 (R), and a vehicle-treated, affected dog. Pupil
responses are shown as percent of baseline pupil area. PLRs are in response to a
stimulus of 10 log photons/cm2/s.severe deﬁcits in inner retinal function as illustrated by reduction of
the ERG b-wave amplitude.
Analysis of sustained pupil size after a bright stimulus (15 log
photons/cm2/s) revealed a signiﬁcant delay (p < 0.05) in secondary
redilation of the pupil to baseline size in rhTTP1 treated CLN2-
affected dogs (Fig. 8), similar to deﬁcits found in untreated dogs
(Whiting et al., 2013a). This deﬁcit in secondary redilation was
present for all CLN2-affected dogs, even those treated with rhTPP1
enzyme that exhibited normal values for other PLR parameters
including constriction amplitude, latency, constriction velocity, and
initial redilation velocity (Group R). The rate of secondary redilation
was signiﬁcantly reduced in treated, affected dogs compared with
genetically normal dogs between 8 and 12 months of age, indi-
cating that post-illumination pupil constriction persisted longer
after light offset in these dogs than in normal dogs.
3.3. ERG
Deﬁcits in both scotopic and photopic ERG b-wave amplitudes of
CLN2-affected dogs that were treated with rhTPP1 at any dose level
were very similar to those of untreated, affected dogs (Fig. 9). CLN2-
affected, treated dogs from group R that exhibited normal PLR pa-
rameters show no improvement in b-wave amplitude compared
with either untreated and vehicle treated dogs or treated dogs that
showed no improvement in PLR parameters (group NR).Fig. 4. PLR constriction amplitudes from 10 month old dogs (mean ± SEM). Treated
data is broken into two groups of dogs with Group R (n ¼ 3) showing a response to
treatment and having normal constriction amplitudes that are signiﬁcantly different
from those of vehicle treated and untreated, CLN2-affected dogs (*, p  0.001; z,
p < 0.025). Treated dogs from Group NR (n ¼ 5) show no response to treatment and
mimic deﬁcits seen in the untreated and vehicle treated dogs (n ¼ 5).
Table 2
Treatment group sample sizes for PLR & ERG recordings with CLN2-affected dogs.
Group Treatment
administered
n for given age in months:
8 10 12 15
R(Response to treatment) 4 mg rhTPP1 2 2 1 e
16 mg rhTPP1 1 1 1 1
NR(No response to
treatment)
4 mg rhTPP1 1 1 1 e
16 mg rhTPP1 2 2 1 1
48 mg rhTPP1 2 2 1 e
Diseased control Untreated 5 4 e e
Vehicle 3 1 e e
Fig. 5. PLR Parameters from 10 month old dogs (mean ± SEM) including latency (A),
average constriction velocity (B), and average redilation velocity (C). Treated dogs from
Group R (n ¼ 3) showed a response to treatment and exhibited PLR parameters that are
signiﬁcantly different from those of vehicle treated and untreated, CLN2-affected dogs
(n ¼ 5) (*, p < 0.05).
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Although optic nerve samples from all dogswere prepared using
the samemethods, the quality of ﬁxation required to obtain reliable
total axon counts was only adequate in 5 of the normal, 3 of the
vehicle-treated affected dogs, and 2 of the TPP1-treated affected
dogs (the latter 2 samples were not included in the quantitative
analyses). No signiﬁcant differences were observed between the
vehicle-treated, affected and normal dogs for either total axon
numbers or in the distribution of axon sizes between the large and
small categories (Table 3). Due to the variance within each group,
the statistical power of this comparison was low (0.11). It may have
been possible to detect a disease-related loss of ganglion cells had a
larger number of dogs been evaluated. Power analyses indicated
that based on the variance of the data within each group the
number of dogs that would have been required to detect a 10%
difference in mean axon numbers was 13 dogs per group with a
statistical power of 0.8 and an alpha of 0.05 (assuming the larger
number of dogs reduced the standard deviation within each group
to 13,000). Clearly if this many dogs were required to detect a 10%
difference in axon numbers, any such difference is not meaningful
with regard to disease mechanism or treatment effects.4. Discussion
rhTPP1 ERT administered directly to the brain via the CSF was
able to delay PLR deﬁcits associated with CLN2 disease in some
dogs, despite the fact that these treatments did not inhibit the
decline in retinal function detectable with ERG. CLN2-affected dogs
that showed treatment effects of enzyme replacement displayed
normal PLR constriction amplitude through 10 months of age and
didn't begin to display deﬁcits until 12 months of age. This is a
substantial improvement relative to the untrreated and vehicle
treated, affected dogs which began to exhibit deﬁcits by 6months of
age that progressed through end-stage disease at 10 months of age.
The PLR depends on the function of both the retina and speciﬁc
nuclei in the midbrain. All of these tissues exhibit an accumulation
of disease-related storage material in CLN2-affected dogs, indi-
cating that TPP1 function is important in both the retina and in
these areas of the CNS (Katz et al., 2008; Whiting et al., 2013a).
Based on the CSF circulation, the only retinal neurons expected to
possibly take up rhTPP1 infused into the CSF are the ganglion cells,
which may be able to take up the enzyme from the CSF circulatingFig. 6. PLR constriction amplitudes from 12 month old dogs (mean ± SEM). Ampli-
tudes are reduced from normal in CLN2-affected dogs which initially responded to
treatment (group R; n ¼ 2) and exhibited normal PLR parameters. The development of
these deﬁcits indicates a waning treatment effect. However, constriction amplitudes in
this group are still signiﬁcantly greater (z, p < 0.05) than those of the dogs that
exhibited no response to enzyme treatment (NR; n ¼ 4) for stimuli of 9 and 10 log
photons/cm2/s. None of the affected, untreated or vehicle treated dogs lived to be 12
months of age.
Fig. 7. PLR constriction amplitude changes with age for rhTPP1 treated dogs from
group R (top) and group NR (bottom) (mean ± SEM). Group R shows a delay in the
development of deﬁcits in PLR constriction amplitude, but at 15 months of age, the
dogs from each group exhibit very similar results. Only one R and one NR dog lived to
the age of 15 months. See Table 2 for all sample sizes.
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on the optic nerve axon count data, it does not appear that the
disease results in loss of retinal ganglion cells, so the effect of the
treatment in preserving the PLR in some dogs is not due to pre-
vention of ganglion cell death, regardless of whether TPP1 got to
these cells via the CSF. The disease also had no effect on the size
distribution of the optic nerve axons, indicating that NCL did not
result in swelling or shrinkage of these axons. It is unlikely that
signiﬁcant TPP1 was able to reach the cells of the inner retina,
which undergo severe degeneration in CLN2 disease (Katz et al.,
2008). Consistent with this expectation, rhTPP1 administered via
the CSF did not result in any improvement in the ERG b-wave,
which reﬂects activity of retinal neurons with cell bodies located in
the retinal inner nuclear layer. Based on these data, it seems likely
that the infused enzymewas able to normalize the PLR primarily by
preserving the function of CNS neurons involved in mediating the
PLR including the pretectal and oculomotor nuclei. Although the
disease-related decline in the PLR was not associated with ganglionFig. 8. The secondary redilation phase of the PLR is delayed in all treated, CLN2-
affected dogs between 8 and 12 months of age. The rate of secondary redilation was
signiﬁcantly decreased from normal (*, p < 0.05) indicating that constriction persists
longer after light offset in these dogs than in normal dogs. See Table 2 for sample sizes.cell loss, it is possible that CLN2 disease affected ganglion cell
function, including the function of intrinsically photosensitive
retinal ganglion cells (ipRGCs) that are involved in mediating the
PLR but do not contribute to the ERG (Pickard and Sollars, 2012).
It is possible that preservation of the PLR by rhTPP1 adminis-
tration in some of the dogs resulted from uptake of the enzyme
from the CSF by the brain and spinal cord neurons involved in
mediating the PLR. Indeed, we previously demonstrated that
infusion of rhTPP1 into the CSF resulted in widespread uptake of
active TPP1 enzyme into many brain regions (Vuillemenot et al.,
2011), including the brain nuclei involved in the PLR (unpub-
lished data). In untreated affected dogs there is widespread pro-
gressive brain atrophy that likely includes loss of or at least
functional impairment of the central nervous system neurons
involved in the PLR. Restoration of TPP1 enzyme to these cells is
likely to preserve their function and survival.
Even in dogs that demonstrated a preservation of the PLR in
response to rhTPP1 infusions, the treatment effect was temporary,
and declines in the PLR responses continued with advancing age.
This suggests that CSF administration may have only partially
restored intracellular TPP1 activity levels in neurons in the PLR
pathway. The result may have been a slowing in the rate of pro-
gression of disease pathology at the cellular level, but not a com-
plete prevention. Optimizing delivery of functional TPP1 enzyme
throughout the brain and delivering the enzyme to the retina as
well may result in more prolonged or even complete preservation
of the PLR.
The efﬁcacy of CSF administration of rhTPP1 in preserving the
PLR was variable, with only one-third of affected dogs that were
treated exhibiting PLR preservation. This may be due to long term
variability in the route of rhTPP1 administration, as the number of
infusions for each route (ICV, ITL, bolus injection) differed for each
dog. In addition, the variability in pharmacological effect may have
been due in part to differences in the distribution of rhTPP1 due to
variations in CSF ﬂow and enzyme uptake by different brain
structures. Such variability would be expected based on the known
ﬂow dynamics of CSF. Quantitative assessments indicated that at
the time of euthanasia, there was substantial variability in TPP1
levels in the same brain regions between dogs that had received the
same dose of rhTPP1 (unpublished data).
The fact that some rhTPP1 treated dogs did display PLR pres-
ervation indicates that this effect is possible with CSF administra-
tion of rhTPP1. In order to optimize the treatment it will be
important to identify the variables that determine efﬁcacy so that
preservation of the PLR, as well as of other neurological functions,
can be achieved consistently. Although the critical variables that
determined efﬁcacy could not be identiﬁed based on the current
study, there was no correlation between rhTPP1 dose and PLR
preservation, so it seems unlikely that simply increasing the
amount of therapeutic protein administered would enhance the
treatment effect relative to preserving the PLR.
Both treated and untreated, CLN2-affected dogs exhibited delays
in the secondary redilation phase of the PLR. Melanopsin input to
the PLR is responsible for the prolonged constriction typical after
offset of a sufﬁciently bright stimulus (Kankipati et al., 2010;
Markwell et al., 2010; Dacey et al., 2005). It is possible that the
reduced rate of secondary redilation in older affected dogs may
reﬂect altered sympathetic input to the iris, and/or altered effect on
the ipRGCs from OFF-bipolar and amacrine cells which both pro-
vide inhibitory input (Belenky et al., 2003; Brown and Lucas, 2009).
The slower secondary post-illumination redilation seen in affected
dogs is consistent with an up regulation of the melanopsin-driven
intrinsic photoresponse as a consequence of a reduction in outer
retinal inputs as evidenced by the reduction in the b-wave of the
ERG. rhTPP1 was unable to normalize this phase of the PLR despite
Fig. 9. ERG a-wave (A,B) and b-wave (CeF) amplitudes (mean ± SEM) as a function of age in normal and CLN2-affected Dachshunds. ERG deﬁcits are similar in CLN2-affected dogs
that were untreated and those that received TPP1 ERT. ERG a-wave amplitude from 10 cd s/m2 scotopic (A) and photopic (B) recordings. ERG b-wave amplitude from scotopic rod
responses (C), scotopic mixed responses from rods and cones at 10 cd s/m2 (D), photopic cone recordings (E), and photopic 30 Hz ﬂicker recordings (F). Treated dogs from Group R
that exhibited normal PLR constriction amplitudes, exhibit no improvement in ERG b-wave amplitude.
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did not appear to attenuate retinal degeneration, this may indicate
a lack of retinal inhibition as the source of these redilation abnor-
malities. However, due to the variable distribution of rhTPP1 when
administered via the CSF, it is possible that the central and pe-
ripheral sympathetic neurons involved in the slow redilation phase
of the PLR did not receive therapeutic amounts of TPP1 in some
dogs, and degeneration of these areas contributed to the delays in
secondary redilation.
The timing of changes in the PLR associated with CLN2 disease
did not coincide closely with changes in ERG responses or with
neurologic signs caused by neuronal degeneration. In untreated
and vehicle treated dogs, mild PLR changes occur early in theTable 3
Optic nerve axon numbers and size distribution.
Disease status Total axon number % Large axonsc
Normala 158,617 ± 16,611 7.5 ± 1.8
Affectedb 136,429 ± 18,258 9.3 ± 1.9
Data are mean ± SD.
a Normals include 3 vehicle-treated dogs and 2 dogs that received the 16 mg dose
of rhTPP1.
b Affecteds include 3 vehicle-treated dogs.
c Percent of axons larger than 7.8 mm2 in cross-sectional area.disease at 6e8 months of age, which coincides with the most
rapidly progressing deﬁcits in the ERG. However, no large changes
occur in the ERG after 8 months of age while the most extreme PLR
deﬁcits occur at 10months of age and coincide with the appearance
of severe neurologic deﬁcits, thus supporting CNS disease. In dogs
treated with ERT, the timing of declines in ERG responses was not
altered. These ﬁndings suggest that alterations in central neural
pathways play a predominant role in the development of PLR def-
icits in canine CLN2. However, the lag between the declines in the
PLR relative to those in the ERG may also be due in part to the
signiﬁcantly lower threshold of the PLR compared with the ERG
(Whiting et al., 2013b). There is likely a complicated interaction of
deﬁcits in the retina and other CNS areas involved in modulating
the PLR. Further analysis of these tissues at various disease stages
would be needed to fully explain the mechanisms involved in PLR
decline and the efﬁcacy of ERT in preserving the PLR in some dogs
despite profound ERG deﬁcits.
The inability of CSF-administered rhTPP1 to preserve the ERG
indicates that while this treatment may have profound beneﬁts in
inhibiting the progression of many neurological deﬁcits (Katz et al.,
2013) it is unlikely to preserve vision. However, like the rest of the
nervous system, retinal cells should be able to take up TPP1 from
their close environment and incorporate it in active form into their
lysosomes. Therefore, in order to preserve vision in CLN2, it may be
necessary to restore TPP1 activity in the eye via ERT directly. If
R.E.H. Whiting et al. / Experimental Eye Research 125 (2014) 164e172172current clinical trials of ICV administered rhTPP1 are successful in
attenuating neurodegeneration, administration directly to the
ocular tissues may be indicated.
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